SecBot SecBot
SECBOTREPLAY Home › Report › AZN

AZN · The Delaware Court of Chancery ruled that Syntimmune (acquired by…

ASTRAZENECA PLC · COURT-RULING filed May 26, 2026 at 20:00 ET

At the news

NEUTRALIMPACT 4/10

COURT-RULING filed May 26, 2026 at 20:00 ET

The Delaware Court of Chancery ruled that Syntimmune (acquired by AstraZeneca/Alexion) breached its merger agreement representation regarding cGMP compliance of drug substance and drug product lots. The court awarded AstraZeneca approximately $11.1 million in indemnification for replacement manufacturing costs, but denied its claim for ~$375 million in benefit-of-the-bargain damages as speculative. The ruling is a modest financial win for AZN but represents a small fraction of the $580B market cap.

  • Court found Syntimmune breached Section 4.13(a) of the merger agreement by failing to manufacture drug lots in compliance with cGMP standards
  • AstraZeneca awarded $11,115,556.33 in indemnification for replacement drug substance and drug product costs
  • Court denied AstraZeneca's claim for ~$375 million in benefit-of-the-bargain damages as entirely speculative and unsupported by evidence
  • The ruling resolves a post-acquisition dispute over contaminated drug materials that caused clinical trial delays

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access